Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09INF
|
|||
| Former ID |
DCL000860
|
|||
| Drug Name |
Laquinamod
|
|||
| Synonyms |
Laquinimod sodium; Laquinimod Sodium Salt; 248282-07-7; UNII-4H914M0CSP; Laquinimod sodium [USAN]; TV-5600; 4H914M0CSP; ABR-215062 SODIUM; Laquinimod sodium (USAN); sodium 5-chloro-3-(ethyl(phenyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-olate; SAIK-MS compound; ABR 215062 Sodium; SCHEMBL1991182; CHEMBL2103814; DTXSID50179538; QCR-166; JWHPPWBIIQMBQC-UHFFFAOYSA-M; AKOS027326368; TV 5600; FT-0670730; D08938; Sodium 5-chloro-3-(ethylphenylcarbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin- 4-olate; 3-Quinolinecarboxamide, 5-chlo
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 3 | [1] | |
| Company |
Active Biotech; Teva
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16ClN2NaO3
|
|||
| Canonical SMILES |
CCN(C1=CC=CC=C1)C(=O)C2=C(C3=C(C=CC=C3Cl)N(C2=O)C)[O-].[Na+]
|
|||
| InChI |
1S/C19H17ClN2O3.Na/c1-3-22(12-8-5-4-6-9-12)19(25)16-17(23)15-13(20)10-7-11-14(15)21(2)18(16)24;/h4-11,23H,3H2,1-2H3;/q;+1/p-1
|
|||
| InChIKey |
JWHPPWBIIQMBQC-UHFFFAOYSA-M
|
|||
| CAS Number |
CAS 248282-07-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C motif chemokine 2 (CXCL2) | Target Info | Modulator | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| NF-kappa B signaling pathway | ||||
| NOD-like receptor signaling pathway | ||||
| TNF signaling pathway | ||||
| Salmonella infection | ||||
| Legionellosis | ||||
| NetPath Pathway | IL-7 Signaling Pathway | |||
| IL1 Signaling Pathway | ||||
| IL4 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| IL5 Signaling Pathway | ||||
| Panther Pathway | CCKR signaling map ST | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Cytokines and Inflammatory Response | |||
| Spinal Cord Injury | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.